How patents for transgenic mice got caught in a sufficiency trap

In a blow for Regeneron Pharmaceuticals, the UK Supreme Court has reversed a Court of Appeal decision by ruling that its patents relating to transgenic mice are invalid due to lack of “sufficiency”.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Biotech

10x Genomics dealt major blow in sequencing fight

20 August 2026 Three disputed sequencing patents took the spotlight as the Federal Circuit weighed challenges to a trio of PTAB rulings.

Biotech

Europe’s missing biotech bridge: Why IP ownership matters more than capital access

17 August 2026 Europe’s biotechnology challenge is not only whether it can fund innovation. It is whether it can continue to originate and control the foundational IP positions from which future biotech value is created. Paul Calvo of Sterne Kessler explains.

Biotech

Masimo keeps $634m smartwatch award and moves to appeal

21 July 2026 Now a Danaher subsidiary, the company is contesting a number of orders after a California court finalised several aspects of the high-profile dispute.

More features

10x Genomics dealt major blow in sequencing fight

Europe’s missing biotech bridge: Why IP ownership matters more than capital access

The ‘Triple Point’ professional: Why patent success requires science, law, and technology

The UPC plugs another gap in its procedural rulebook

Patent litigator joins Baker Botts in London as UPC grows in significance

Where Big Pharma is betting big in the M&A boom

Buying the brains: Why is Big Pharma shopping for innovation?

FisherBroyles and Hong Kong affiliate draft in senior partners

How patents for transgenic mice got caught in a sufficiency trap

More on this story

Editor's picks

Editor's picks

More features